Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd
Summary
This study aims to evaluate the efficacy of Adebrelimab plus concurrent chemoradiotherapy compared with placebo plus concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer by evaluating progression-free survival (PFS).
Official title: A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Key Details
Gender
FEMALE
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
720
Start Date
2025-10-17
Completion Date
2028-12
Last Updated
2025-11-17
Healthy Volunteers
No
Conditions
Interventions
SHR-1316 Injection
SHR-1316 injection.
Cisplatin Injection
Cisplatin injection.
Carboplatin Injection
Carboplatin injection.
Paclitaxel Injection
Paclitaxel injection.
SHR-1316 Placebo Injection
SHR-1316 placebo injection.
Locations (1)
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China